These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 26254225

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L.
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
    Tam EM, Runyon ST, Santell L, Quan C, Yao X, Kirchhofer D, Skelton NJ, Lazarus RA.
    J Mol Biol; 2009 Jan 09; 385(1):79-90. PubMed ID: 18973760
    [Abstract] [Full Text] [Related]

  • 5. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H, Fan F, Liu Z, Shen C, Wang A, Lu Y.
    Cancer Chemother Pharmacol; 2015 Aug 09; 76(2):307-15. PubMed ID: 26063323
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS.
    Cancer Lett; 2013 May 10; 332(1):74-82. PubMed ID: 23348694
    [Abstract] [Full Text] [Related]

  • 10. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY, Jiao DM, Wu YQ, Chen J, Wang J, Tang XL, Mou H, Hu HZ, Song J, Yan J, Wu LJ, Chen J, Wang Z.
    Oncotarget; 2016 Apr 05; 7(14):18247-61. PubMed ID: 26919096
    [Abstract] [Full Text] [Related]

  • 11. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
    Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.
    Cancer Res; 2015 Aug 15; 75(16):3373-83. PubMed ID: 26141862
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.
    Breast Cancer Res Treat; 2011 Nov 15; 130(1):85-96. PubMed ID: 21181437
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
    Cao HH, Cheng CY, Su T, Fu XQ, Guo H, Li T, Tse AK, Kwan HY, Yu H, Yu ZL.
    Mol Cancer; 2015 May 14; 14():103. PubMed ID: 25971889
    [Abstract] [Full Text] [Related]

  • 20. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR, Lal B, Ho S, Woodard CL, Zhou X, Taeger A, Xia S, Laterra J.
    Anticancer Drugs; 2011 Oct 14; 22(9):905-12. PubMed ID: 21654317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.